Study of Apatinib and MASCT in Patients With Advanced Solid Tumors

NCT02844881 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumors
Excluding T Cell Lymphoma

Interventions

DRUG: Apatinib
BIOLOGICAL: MASCT

Sponsor

The First People's Hospital of Lianyungang

Collaborators

[object Object]